Möchten Sie immer auf dem neuesten Stand bleiben?

ADMA Biologics (NASDAQ:ADMA) Channel Stuffing Claims Trigger Securities Fraud Class Action – Investors Notified to Contact BFA Law about the Lawsuit

ADMA Biologics Investors that Lost Money after Channel Stuffing Allegations are Notified to Contact BFA Law about the Filed Securities Fraud Class Action

Exton, PA, July 07, 2026 (GLOBE NEWSWIRE) -- While the treatment landscape for systemic lupus erythematosus (SLE) continues to evolve with increasing biologic adoption and a growing pipeline of...

ADMA Biologics Sued for Securities Fraud After Channel Stuffing Claims Spark a 29% Stock Drop – Investors Notified to Contact BFA Law by August 10

ADMA Biologics Accused of Making Misrepresentations about its Revenue Sources in Securities Fraud Class Action – Investors Notified to Contact BFA Law

Silver Spring, MD, July 01, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic...

ADMA Biologics Investors Bring Securities Class Action Following Channel Stuffing Allegations – Contact BFA Law by August 10 Deadline

Drug developers have a new, optimized option for U.S.-based manufacturing, as AGC Biologics enters a strategic partnership with Pyramid Pharma Services.

Intravacc Highlights Four Integrated Vaccine Development Platforms for CDMO Partners

Investor Announcement: ADMA Biologics Investors are Notified to Contact BFA Law about the Pending Securities Fraud Class Action to Recover Stock Losses